Remission criteria for schizophrenia: Evaluation in a large naturalistic cohort

被引:93
作者
De Hert, Marc
van Winkel, Ruud
Wampers, Martien
Kane, John
van Os, Jim
Peuskens, Joseph
机构
[1] Catholic Univ Louvain, Univ Psychiat Ctr, B-3070 Kortenberg, Belgium
[2] Maastricht Univ, Dept Psychiat & Neuropsychol, EURON, S Limburg Mental Hlth Res & Teaching Network, NL-6200 MD Maastricht, Netherlands
关键词
schizophrenia; outcome; remission;
D O I
10.1016/j.schres.2007.01.010
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Recently, remission criteria for schizophrenia have been proposed, based on low symptom severity of core symptoms (severity criterion), sustained over minimally 6 months (time criterion). Little is known, however, about the added value of the time criterion in addition to the cross-sectional severity criterion. Methods: In order to evaluate whether remission is a valid concept for daily clinical practice, the cumulative incidence of patients meeting remission criteria was evaluated in a large naturalistic prospective study of patients with schizophrenia or schizoaffective disorder in different treatment settings in Belgium. The impact of being in remission on global and daily functioning was evaluated. Results: Over time, nearly I out of 3 patients with a diagnosis of schizophrenia or schizoaffective disorder (29%) met criteria for remission at study endpoint. Patients in remission had better insight in their disorder, a higher level of global functioning and functioned better with respect to daily living tasks, both compared to patients never meeting remission criteria and to patients only meeting the severity criterion but not the time criterion. Of the patients not meeting remission criteria at baseline, 21% attained remission at study endpoint. Conclusion: The remission severity and time criteria appear to combine into a valid concept for daily clinical practice and should be a target for treatment. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:68 / 73
页数:6
相关论文
共 16 条
  • [1] Remission in schizophrenia: Proposed criteria and rationale for consensus
    Andreasen, NC
    Carpenter, WT
    Kane, JM
    Lasser, RA
    Marder, SR
    Weinberger, DR
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (03) : 441 - 449
  • [2] CARR VJ, 1983, SCHIZOPHR B, V9, P98
  • [3] Pharmacological treatment of hospitalised schizophrenic patients in Belgium
    De Hert, M.
    Wampers, M.
    Peuskens, J.
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2006, 10 (04) : 285 - 290
  • [4] Validation study of PECC (Psychosis Evaluation tool for Common use by Caregivers):: Interscale validity and inter-rater reliability
    De Hert, M
    Wampers, M
    Thys, E
    Wieselgren, IM
    Lindström, E
    Peuskens, J
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2002, 6 (03) : 135 - 140
  • [5] DEHERT M, IN PRESS PSYCHIAT RE
  • [6] Guy W., 1976, Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD, U.S. Department of Health, Education, and Welfare, Public health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, DHEW Publ No ADM 76-338, pp 218-222., P218
  • [7] Remission and cognitive ability in a cohort of patients with schizophrenia
    Helldin, Lars
    Kane, John M.
    Karilampi, Ua
    Norlander, Torsten
    Archer, Trevor
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2006, 40 (08) : 738 - 745
  • [8] A BRIEF MENTAL-HEALTH OUTCOME SCALE - RELIABILITY AND VALIDITY OF THE GLOBAL ASSESSMENT OF FUNCTIONING (GAF)
    JONES, SH
    THORNICROFT, G
    COFFEY, M
    DUNN, G
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1995, 166 : 654 - 659
  • [9] Kane JA, 2003, J CLIN PSYCHIAT, V64, P5
  • [10] Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection
    Lasser, RA
    Bossie, CA
    Gharabawi, GM
    Kane, JM
    [J]. SCHIZOPHRENIA RESEARCH, 2005, 77 (2-3) : 215 - 227